Alzheimer Disease Clinical Trials in Syracuse, New York

4 studies are recruiting for alzheimer disease in Syracuse, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

    This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

    Stage
    Phase 2
    Ages
    55 to 90
    Site
    Research Central LLC (DBA Ichor Research), Syracuse, New York
    Locations
    78 in total
    Run by
    Celgene

    See if you can join NCT06808984 on ClinicalTrials.gov

  2. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

    Stage
    Phase 3
    Ages
    55 to 90
    Site
    SUNY Upstate Medical University, Syracuse, New York
    Locations
    293 in total
    Run by
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT06585787 on ClinicalTrials.gov

  3. [18F]PI-2620 Phase 3 Histopathological Study

    This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after de…

    Stage
    Phase 3
    Ages
    50 and older
    Site
    Ichor Research, Syracuse, New York
    Locations
    25 in total
    Run by
    Lantheus Biosciences Ltd.

    See if you can join NCT05641688 on ClinicalTrials.gov

  4. Clinical Trial on Agitation in Alzheimer's Dementia

    The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

    Stage
    Phase 2
    Ages
    60 and older
    Site
    Ichor Research, Syracuse, New York
    Locations
    31 in total
    Run by
    IGC Pharma, LLC

    See if you can join NCT05543681 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.